MedTrace Logo

ICS Treatment Compliance of Asthma Patients

NCT02990117 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2019-08-14

No results posted yet for this study

Summary

The introduction of inhaled medication as the primary treatment for asthma has led to substantial improvements in asthma control \[1, 2\]. However, uncontrolled asthma is still common and represents a considerable burden to patients and society \[3, 4\]. An important reason for poor asthma control and consequently, increased healthcare expenditure is suboptimal adherence to the prescribed regimen \[5-7\].

Real-world market research study in hospitals across China reported that physicians perceived that only 23% of patients were fully compliant with their medication regime (77% non-adherent), compared to 55% in the European Union and 63% in the US \[AZ internal document\]. The physician reported rate of full adherence was lower than the patient-reported rate (38%). Poor patient adherence was the challenge most frequently mentioned (by 41% of physicians) when treating an asthma.\[8\]

However

There is some evidence on the drivers of patient behaviour around low adherence but more depth research is needed

There is little evidence on variation of determinants of asthma inhaled treatment across different age of group

Our research aims to address above data gap Mean while this research can guide the development of new module on Red Scarf patient education program.

Conditions

  • Asthma, Allergic

Interventions

OTHER

No Intervention

No Intervention

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • First Affiliated Hospital Xi'an Jiaotong University

    lead OTHER

Principal Investigators

  • Manxiang Li, PhD · First Affiliated Hospital Xi'an Jiaotong University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2018-01-20
Completion
2018-01-20

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02990117 on ClinicalTrials.gov